ArticleHealth science reports2026
Decreasing Serum Adropin Levels in Patients With Systemic Lupus Erythematosus: A Case-Control Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systematic lupus erythematosus is a complex fundamental autoimmune disease with relapsing-remitting course and spectrum of disease ranging from mild to life-threatening illness. Approximately half of women diagnosed with systemic lupus erythematosus (SLE) are affected by obesity, with rates reaching up to 50%. Adropin, a peptide hormone, plays a crucial role in regulating lipid and glucose metabolism while exhibiting protective effects against oxidative stress and inflammation. It further modulates the immune response. Given these functions, our study aimed to explore variations in the serum levels of adropin among patients diagnosed with SLE. Additionally, we sought to investigate its association with coronary risk factors and the clinical manifestations of the disease. Method and Material: In this cross-sectional study, we included 59 SLE patients and 30 age-matched healthy individuals. Utilizing high sensitivity human ELISA kits, we measured serum adropin levels. Result: The SLE group exhibited significantly lower serum adropin levels compared to the control group (0.41 vs. 0.69 ng/mL, Conclusion: Our study revealed a significant decrease in serum adropin levels among patients with SLE compared to healthy controls. The independent association between serum adropin levels and HTN suggests that adropin may serve as a potential predictor of coronary artery disease in individuals with rheumatic diseases. Results deepen our understanding of adropin in SLE, emphasizing its clinical relevance for assessing cardiovascular risk in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.